Related Experiment Videos
Effect of Extended-Duration Venous Thromboprophylaxis After Cancer Surgery
Xing Wang1,2, Wuqian Chen1, Lu Ma1
1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Background:
Cancer patients undergoing surgery are at significantly increased risk of venous thromboembolism (VTE). Although extended thromboprophylaxis is recommended, the optimal anticoagulant type and duration remain unclear. This study aimed to evaluate the comparative efficacy and safety of different extended thromboprophylaxis in this population.
Methods:
A Bayesian network meta-analysis of randomized controlled trials (RCTs) was performed to evaluate various thromboprophylaxis strategies for patients undergoing cancer-related surgery. We conducted both three-node and five-node network analyses to evaluate extended-duration versus standard-duration thromboprophylaxis strategies. Outcomes included venous thromboembolism, major bleeding, and all-cause mortality. Net clinical benefit and risk-benefit assessments were additionally performed to determine the overall impact of prolonged anticoagulant therapy. Treatment effects were summarized as risk ratios (RRs) with corresponding 95% credible intervals (CrIs).
Results:
A total of 14 randomized controlled trials involving 4,331 participants were included. Compared with placebo, extended-duration prophylaxis with direct oral anticoagulants (DOACs) (RR 0.12, 95% CrI 0.05-0.27) and low-molecular-weight heparin (LMWH) (RR 0.17, 95% CrI 0.05-0.55) significantly reduced the incidence of venous thromboembolism without a corresponding increase in major bleeding. In net clinical benefit analyses, both prolonged DOAC therapy (RR 0.27, 95% CrI 0.14-0.49) and LMWH (RR 0.36, 95% CrI 0.17-0.76) demonstrated favorable overall outcomes. Risk-benefit evaluation suggested that prolonged DOACs provided a more advantageous balance than LMWH, with an NNH/NNT ratio of 4.17.
Conclusions:
Extended thromboprophylaxis is effective and safe for cancer patients undergoing surgery. Besides, DOACs appears to be the optimal anticoagulant for extended thromboprophylaxis, providing the greatest net clinical benefit.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism III: Nursing Management